Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.1% cyclosporine A cationic nanoemulsion for perennial allergic conjunctivitis
ChiCTR2600131434Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of cyclosporine in atopic conjunctivitis (2 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Sign score at 3 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
atopic conjunctivitis
Beyond the preview
Go deeper on ChiCTR2600131434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131434.